Edward Carr Sells 43,682 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) CAO Edward Carr sold 43,682 shares of the business’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $3,559,646.18. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Dianthus Therapeutics Trading Down 3.1%

DNTH stock opened at $77.86 on Friday. The firm has a 50-day moving average price of $52.53 and a 200-day moving average price of $42.69. Dianthus Therapeutics, Inc. has a 12 month low of $13.36 and a 12 month high of $88.02. The stock has a market capitalization of $3.46 billion, a P/E ratio of -18.99 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Monday, March 9th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.46). The company had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. As a group, equities analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Trending Headlines about Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Company news: management announced an early Phase‑3 “go” decision and an upsized capital raise that sparked the recent rally; market reaction was enthusiastic because the program advancement de‑risked the story while the raise funds development and operations. Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision
• Positive Sentiment: Financing closed: Dianthus completed an upsized underwritten offering that generated roughly $719M of gross proceeds (including full exercise of the underwriters’ option), strengthening the company’s cash runway for clinical work. This is a clear near‑term liquidity positive for investors. Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering…
• Positive Sentiment: Analyst upgrades: multiple firms (Raymond James, Wedbush, Robert W. Baird) issued bullish notes or raised their stance, which helped lift sentiment and trading activity. Upgrades add distribution and can attract momentum buyers. Dianthus Therapeutics (NASDAQ:DNTH) Raised to “Strong-Buy” at Raymond James Financial
• Positive Sentiment: Trading flow: the stock saw a large volume increase after analyst coverage/bullish headlines, indicating active repositioning by investors around the financing and clinical update. Higher volume can amplify price moves in either direction. Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase Following Analyst Upgrade
• Neutral Sentiment: Short-interest note: the most recent short‑interest data reported an anomalous zero‑share figure and essentially a 0.0 days‑to‑cover metric — likely a reporting quirk rather than a meaningful signal; treat with caution.
• Negative Sentiment: Analyst/model risk: HC Wainwright lowered near‑term and FY2026–FY2028 EPS forecasts substantially even while keeping a Buy rating and a high target; the cuts highlight expected cash burn and timing risk, which can pressure near‑term sentiment and invite profit‑taking.
• Negative Sentiment: Operational/financial backdrop: recent quarterly results included an EPS miss and very negative margins/returns, reminding investors that Dianthus remains a pre‑profit, high‑burn biotech—so upside is dependent on clinical progress and successful use of the new capital.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Patient Square Capital LP acquired a new position in Dianthus Therapeutics in the third quarter valued at approximately $4,919,000. XTX Topco Ltd acquired a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $503,000. Sio Capital Management LLC increased its stake in shares of Dianthus Therapeutics by 101.8% in the 2nd quarter. Sio Capital Management LLC now owns 236,070 shares of the company’s stock valued at $4,398,000 after acquiring an additional 119,073 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Dianthus Therapeutics by 13.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,642,198 shares of the company’s stock valued at $64,620,000 after acquiring an additional 196,117 shares in the last quarter. Finally, Ensign Peak Advisors Inc acquired a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at $2,504,000. Institutional investors own 47.53% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. Oppenheimer increased their price target on Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a research note on Monday, March 9th. Truist Financial boosted their price objective on Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Stifel Nicolaus set a $120.00 target price on Dianthus Therapeutics in a report on Monday, March 9th. Finally, HC Wainwright increased their target price on Dianthus Therapeutics from $47.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, March 9th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $115.33.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.